Incubator At North Brunswick Credited With Over $9B of Economic Impact to New Jersey

The New Jersey Economic Development Authority (NJEDA) today released findings from the NJ Bioscience Center Incubator (BCI) IMPACT Study, a report seeking to understand and quantify the economic impacts of the incubator and the companies it has hosted and nurtured. The results found that BCI has been a vital resource for New Jersey’s life sciences sector and has had a positive impact on the state’s overall economy in terms of job creation, tax revenue, and total economic output. For full report click here.



LinusBIO Named To The Fierce 15

LinusBio’s inclusion in the Fierce 15 list underscores its innovation in pioneering novel biomarkers. LinusBio’s proprietary platform introduces precision exposome sequencing that can facilitate discovery across various health conditions – from autism to gastrointestinal disorders to ALS to renal disease and cancers. LinusBio, a Mt Sinai spin-off, is a resident of the Incubator at North Brunswick.  

BioAegis Recognized by Genetic Engineering News as 1 of 9 Companies Leading Biotech in NJ

BioAegis’ flagship project involves the development of recombinant human plasma gelsolin (rhu-pGSN) for the treatment of acute and chronic inflammatory diseases, including acute respiratory distress syndrome (ARDS). BioAegis is a graduate of the Incubator at North Brunswick and a current resident of Step-Out Labs at North Brunswick.

Bionex Pharma Receives $150,000 Catalyst R&D Grant

Congratulations to Dr. Hock Tan, CEO of Bionex Pharma, for receiving a CSIT Catalyst R&D Grant of $150,000. Bionex is a resident of the Step-Out Labs at North Brunswick and a graduate of the Incubator at North Brunswick.

Welcome Celleqore Inc. to the Incubator at North Brunswick !!

Celleqore is a biotech firm that provides the following specialty lab R&D services:

-       Full-spectrum flow cytometry services for cellular analysis

-       In vitro and ex vivo tumor and autoimmune drug efficacy models

-       Biomarker assessments, molecular biological assays, and immunoassays

-       FDA Compliance Services, manufacturing and laboratory validations, GXP protocols

Nicholas Collette is CEO of Celleqore located in Lab #132.

Orthobond Receives FDA DeNovo Approval

Incubator at North Brunswick graduate, Orthobond, recently announced that it achieved a significant milestone with the FDA approval for Ostaguard antibacterial technology. 

TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant 

TAXIS Pharmaceuticals, recently announced that it has received a $2.67 million grant from NIH NIAID. TAXIS Pharmaceuticals is a clinical-stage company developing new classes of anti-resistance agents to treat life-threatening, multidrug-resistant bacterial infections. TAXIS is a graduate of the Incubator at North Brunswick.

PDS Biotech Appoints Stephan Toutain as COO

“We are thrilled to welcome Stephan to the PDS Biotech team as Chief Operating Officer. His invaluable experience spans many aspects of the life sciences industry, from drug development to commercialization, providing a wealth of knowledge to our team,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. PDS is a graduate of the Incubator at North Brunswick.

34 Companies Awarded $68M Through NOL in 2023

2024 NOL Application Deadline is June 30th – apply NOW

The Net Operating Loss (NOL) program allows life sciences companies the opportunity to sell a percentage of their net operating losses and unused R&D tax credits for cash. Up to $75 million/year is available from the NJ program. The application deadline for the 2024 program is June 30^th. For application information, visit NJEDA/NOL now.

Reunion Neuroscience’s $103M A Round

Reunion, a Morristown based clinical-stage biopharmaceutical company focused on neuroscience, recently announced the close of a $103 million Series A financing.

J&J Joins The HELIX

J&J will join a host of other industry and innovation leaders, including the Rutgers Robert Wood Johnson Medical School, RWJBarnabas Health, Hackensack Meridian Health, Rutgers University, Princeton University, the University of Tel Aviv and a number of international companies, including Atlantic Technology Institute from the Republic of Ireland. In December, the HELIX, located in downtown New Brunswick, announced another huge tenant as Nokia Bell Labs said it will move its world-famous research facility to the space.

NJEDA Awards First $2M Under Angel Match Program

NJEDA has closed its first four approvals under the Angel Match Program, awarding a total of $2 million to support early stage technology companies. With a funding pool of $20 million from the federal State Small Business Credit Initiative (SSBCI), the Angel Match Program was launched last year. Under the Angel Match Program, the NJEDA is the first entity to commit capital to a technology company, leading to other investors who provide matching funds.

NJ Life Sciences Report Reveals Thriving Ecosystem

Choose New Jersey, in partnership with JLL, BioNJ and NJEDA, has released the 2024 New Jersey Life Sciences Report, showcasing NJ’s thriving life sciences ecosystem and highlighting its place as a national leader for companies seeking affordable and appropriate lab space, quality of life, and world-class scientific talent.

Incubator Labs at the New Jersey Bioscience Center

The Incubator at North Brunswick has small labs available now !! Email or call New Jersey Bioscience Center Director Lenzie Harcum (732-839-1880) with any questions or to request a tour of the Incubator at North Brunswick. 

New Jersey Bioscience Center, a 300,000 SF, 50 acre research park that includes the Incubator at North Brunswick, with 27 private wet labs and the multi-tenant Step-Out Labs at North Brunswick for growing biotech companies. Larger life sciences space ranging from 5000 – 32,000 SF.

New Jersey Bioscience Center

675 US Highway One,

North Brunswick, NJ 08902

732-839-1880